Clinical trial · Observational
Hormones in Hypogonadotropic Hypogonadism
Hormone Profile in Women With Hypogonadotropic Hypogonadism - a Prospective Pilot Study
NCT04927676CI-TRIAL-00070716unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Therefore, the main objective of this prospective pilot study is to evaluate a complete hormonal profile in women with hypogonadotropic hypogonadism, including anti-mullerian hormone (AMH) and antral follicle count. Changes in this regard will be evaluated after 2 months of individual treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AMH | — | UNRESOLVED | — |
| Follicle Cyst | — | UNRESOLVED | — |
| Hypogonadism, Hypogonadotropic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- AMH
- timeFrame
- 2 months
- description
- Evaluation of a complete hormone profile including AMH in women with HH
- measure
- antral follicle count
- timeFrame
- 2 months
- description
- Evaluation of the antral follicle count in women with HH
Secondary outcomes (2)
- measure
- AMH after 2 months
- timeFrame
- 2 months
- description
- Changes in this parameter studied after 2 months of individual treatment (after starting estrogen/progestin replacement therapy or without treatment)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with HH and secondary amenorrhea. HH is defined as absence of spontaneous menstruation for ≥6 months, no abrupt menstrual bleeding after progesterone therapy, and normal or low serum FSH and LH levels. * The patient gave written informed consent to the study after receiving detailed information and education from medical contributors at the Department of Obstetrics and Gynecology, Medical University of Vienna. * Age between \>18 and \<35 years. Exclusion Criteria: * Latent or manifest hypothyroidism (TSH \>4 micromole/milliliter) or current thyroid hormone replacement therapy. * No existing informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.